LONDON (Reuters) – The COVID-19 vaccine developed by Oxford University and AstraZeneca has 76% efficacy against symptomatic infection for three months after a single dose, with efficacy improving when a second shot is given later, a preprint study showed on Tuesday.
Oxford University said the findings supported a decision made by Britain to extend the interval between initial doses and booster doses of the shot to 12 weeks.
(Reporting by Alistair Smout; Editing by Gareth Jones)
